We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

December 11, 2020

Beyond Covid; what happened in digital health in 2020?

Commentary
Kate O'Reilly
&

Beyond Covid; what happened in digital health in 2020? 

 

There is no doubt that Covid-19 has changed the world that we live in. It has driven innovation in the healthcare sector beyond our imagination. From the development of contact tracing apps, home test kits and test scheduling to apps that remind users to wash their hands, and remote flu symptom monitoring, Covid-19 has been a silver lining for many digital health start-ups.. 


With the unprecedented need for clinically validated therapies combined with relaxed regulatory measures, digital health companies across the therapeutic spectrum were given the opportunity to showcase their chef d'oeuvres. But, with all eyes on Covid, these rarely made the headlines. Here we give air time to the non-Covid highlights and trends over the last twelve months, Our team has handpicked four major therapeutic areas to delve into and capture the most impressive and far-reaching highlights just for you!


Cardiometabolic

In the Cardiometabolic space we saw an explosion of the use of sensors for remote monitoring, particularly in the area of cardiac arrhythmias. In April, Belgium-based FibriCheck, launched a new version of its smartwatch capable of scanning for atrial fibrillation while the wearer is asleep. Their approach, which is based on photoplethysmography (a simple optical technique that measures the rate of blood flow to capture heart rhythm measurements) constitutes the first solution to offer nocturnal AFib screening. Following suit last month we saw VitalConnect launch its VitalPatch® RTM, which leverages a unique AI-based ECG analysis to monitor for 21 types of cardiac arrhythmia. The solution also offers an interim diagnostic report after five days, which is a first-step towards shortening monitoring periods for select patients

In early Autumn Samsung and Fitbit took the spotlight on the regulatory stage following FDA clearance of their smartwatch and ECG app, respectively, both of which are indicated for use in tracking heart rhythm irregularities

Activity in the metabolic domain was sporadic and exotic. In January, one research team at POSTECH developed a Smart Light-emitting diode contact lens that can diagnose diabetes and treat diabetic retinopathy. This manoeuvre vitalises a new trend for ocular wearable diagnostics and therapeutics in diabetes. A few months later in May, Lumen released their home Metabolism Tracking Device revolutionising the way we approach nutrition decision making and denoting the first step to tracking an individual's metabolism outside the lab. Abbott has always been active in the cardiometabolic space owing to its diagnostic product portfolio and this year was no exception. In September, Abbott took one step further to embracing the next-generation user experience with the release of the world’s smallest & thinnest glucose sensor.

 

Mental Health

Given the global psychological burden bestowed by the pandemic, it was of little surprise to see the mental health segment gaining momentum. With the FDA’s temporary policy changes and regulatory reprieve, companies developing digital solutions for psychiatric disorders in 2020 benefited from fast-tracked and breakthrough approvals. Swedish pharma company Orexo was among the most active companies in this area with the rolling out of three new digital therapeutics for treatment of schizophrenia, depression, and alcohol use disorder over the course of the year. 

In June ResApp Health announced the launch of the first at-home sleep apnoea screening tool, SleepCheck. The application, which analyses a user’s breathing and snoring represents the first clinical-grade, regulatory-approved, screening tool for sleep apnoea that is directly accessible to consumers. A few months later Ellipsis Health launched its Rising Higher mobile app, a pioneer in behavioral health and semantic-based assessments for detecting anxiety and depression.

We have probably all heard mention of Akili, the frontline player in the mental health space this year. The company was floodlit for the regulatory success of its ADHD digital therapeutic EndeavorRx. EndeavourRx personifies the first-of-its-kind, non-drug treatment option and first game-based therapeutic approved by the FDA for any condition. This move pivots the treatment of psychiatric disorders towards the direct targeting of neurological function and therapeutic entertainment.

 

Neurology

Neurology is up there among the most active therapeutic areas when we reflect on milestones in digital health during 2020. Pain management was one of the most active and progressive use cases within this segment on foot of several exciting product launches. Abbott’s FDA -cleared radiofrequency ablation device IonicRF, and OmniPEMFs electromagnetic headband for pain relief set the scene in digital analgesia. The neurodegenerative area saw least activity with few product launches and regulatory approvals. Parkinson's Disease was the exception. Abbott’s device-controlled, deep brain stimulation system received expanded indication at the beginning of the year for the management of medication-induced dyskinesia. Cala Health received recognition later in the year when its wrist worn neuromodulation therapy received FDA Breakthrough Device Designation for the treatment of action tremors. These moves exemplify an evolution of holistic, patient-centric care in the neuro-digital space

In June, Masimo announced the launch of Bridge, a wearable neurostimulator designed to reduce opioid withdrawal symptoms. The device, which sits just behind the ear illustrates a critical first step toward successful illicit opioid cessation and treatment.

 

Oncology

Artificial Intelligence met its greatest partner for success in oncology diagnostics. In 2020 oncology set the bar high in terms of leveraging digital to address unmet needs. AI-powered solutions for prostate (Ibex Medical Analytics) and breast cancer detection (University of Waterloo) showed their potential in 2020. Similarly, there was development in the haematology space with FDA clearance of the first-in-world hematology App by Scopio Labs. The AI-powered decision support system gives laboratories an unprecedented ability to capture digital scans, opening the door for morphology-based diagnostics and treatments for various blood cancers. Hologic jumped on the AI-oncology bandwagon, but in cervical cancer. Its novel Genius Digital Diagnostic platform which combines an AI algorithm with advanced digital imaging showed it can help detect pre-cancerous cells in women, and marks one of the first CE-marked cervical cancer screening tools. Genosity took a less familiar and exotic route; detecting relapse. It's biospy monitoring platform was recognised for its ability to earlier detect relapse. Sema4 marked its broad and holistic approach to oncology with the introduction of  “Sema4 Signal™”, a family of data-driven precision oncology solutions, one of the first tools that support oncologists throughout a patient’s journey, from risk assessment to remission.

Remote monitoring has always typified an opportunity in oncology so it is no surprise that 2020 also saw activity here given the urgency to transfer care to the home. In July, Careology launched a remote monitoring platform for cancer care that allows patients to connect with their clinical team and gives clinicians a real-time view of their patients’ health status. Only time and experience will tell, but it is expected that remote monitoring will facilitate early and proactive intervention by clinical teams, having the potential to be lifesaving.

Ending on a high note we witnessed the CE-marking of Oleena, Voluntis’ oncology digital therapeutic only last month. This move paves the way for future commercialisation of digital therapeutics in oncology.

Covid-19 presented an opportunity to stress test every assumption, system, and solution in the digital health industry. And it did. Both disruptive and transformative, the crisis has fast-tracked many healthcare trends that were simmering below the surface. It’s been a whirlwind of a year for digital health beyond the direct effects of the pandemic. Can 2021 measure up?


 

 



We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: DTx last mile delivery: HCPs and Patient adoption (Part 2)

3rd February @ 10:45AM EDT

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: The Regulation of SaMD in the US

14th February @ 10:45AM EDT

Join us in this US-focused Masterclass led by Clay Anselmo and Bernhard Kappe, As they walk us through the regulation of SaMD in the US. Apply now to secure your place.

Featuring
Bernhard Kappe
Bernhard Kappe
Founder & CEO, Orthogonal
Clay Anselmo
Clay Anselmo
VP Quality Assurance and Regulatory Affairs, ENvizion
Featuring
Bernhard Kappe
Bernhard Kappe
Founder & CEO, Orthogonal
Clay Anselmo
Clay Anselmo
VP Quality Assurance and Regulatory Affairs, ENvizion
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx - Pharma partnerships

15th February @ 10:45AM EDT

Join us as we deep dive into DTx-Pharma partnerships, with a focus on how to monetize DTx within the traditional pharmaceutical business model. Apply now to connect with peers and hear from thought leaders in this space.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Mansa Shroff
Mansa Shroff
Head of Partnerships at WKD.SMRT
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Mansa Shroff
Mansa Shroff
Head of Partnerships at WKD.SMRT
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Webinar: DTx commercialisation models - Pharma Partnerships & D2C route

17th February @ 10:00AM EDT

Last month, we did a deep dive on the Employer route to market for DTx products. Join us this month as we look into other potential go-to-market strategies for Digital Therapeutics. Apply now to hear valuable insights from thought leaders in this space.

Featuring
Pierre Leurent
Pierre Leurent
CEO, Voluntis
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee
Featuring
Pierre Leurent
Pierre Leurent
CEO, Voluntis
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Masterclass: Clinical Trials Design for Digital Health products

31st January @ 10:45AM EDT

Join us in this Masterclass led by Click Therapeutics, as we discuss Clinical Trials Design for Digital Health Products. Our Masterclass sessions are the perfect opportunity to hear from thought leaders in the space and share your own thoughts and experiences.

Featuring
Shaheen Lakhan
Shaheen Lakhan
Chief Medical Officer , Click Therapeutics
Featuring
Shaheen Lakhan
Shaheen Lakhan
Chief Medical Officer , Click Therapeutics
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Digital tech for Trial Recruitment and Retention

2nd February @ 10:45AM EDT

Join our Digital Health Meeting led by Laura Gunn from Pharmstars as we discuss digital tech for Trial Recruitment and Retention. This is the perfect opportunity to connect with peers and meet new people working in this space.

Featuring
Laura Gunn
Laura Gunn
Managing Director at PharmStars
George Platings
George Platings
Market Development Specialist at uMotif
Featuring
Laura Gunn
Laura Gunn
Managing Director at PharmStars
George Platings
George Platings
Market Development Specialist at uMotif
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: DTx last mile delivery: HCPs and Patient adoption (Part 2)

3rd February @ 10:45AM EDT

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

Digital Health Solutions with the greatest impact in cancer patients' lives

8th February @ 10:45AM EDT

How can Digital Health improve cancer patients’ lives? Are you working in this industry? Keep reading, this meeting is for you. Join us as we discuss current Digital Health products in oncology and the unmet/gaps need to be addressed.

Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.